Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cells engineered to fight HPV tumors before standard care

NCT ID NCT05639972

First seen Mar 03, 2026 · Last updated May 24, 2026 · Updated 10 times

Summary

This study tests whether a single dose of a patient's own genetically modified immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before standard treatment like chemo-radiation or surgery. About 15 adults with advanced HPV-positive cancers (e.g., cervical, anal, or throat cancer) will receive the cell therapy. The goal is to see if this approach is feasible and improves long-term survival without delaying standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • RWJBarnabas Health - Robert Wood Johnson University Hospital

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rutgers Cancer Institute

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.